文献速递中枢神经肿瘤放疗姑息放疗与转移瘤放疗物理与技术

脑转移瘤重复立体定向放疗的急性毒性与脑累积剂量:184例回顾性研究

Acute toxicities and cumulative dose to the brain of repeated sessions of stereotactic radiotherapy (SRT) for brain metastases: a retrospective study of 184 patients.
PubMed 文献 · Radiat Oncol · 2023-01-10

该回顾性研究分析了2010至2020年间184例脑转移瘤患者接受2至6次立体定向放疗(SRT)的急性毒性及脑累积剂量。36%的患者在至少一次SRT期间出现急性毒性,无3至4级毒性,最常见为1至2级头痛;重复SRT未显著增加急性毒性。即使治疗超过10个累积脑转移瘤,等效全脑放疗剂量(VWBRT)中位数仍低(47.9 ml),脑生物等效剂量远低于全脑放疗。

要点

  • 重复SRT治疗脑转移瘤未出现3至4级急性毒性,1至2级头痛最常见。
  • 连续多次SRT之间急性毒性发生率无显著差异。
  • 即使累积治疗超过10个脑转移瘤,脑累积剂量仍远低于全脑放疗。

核心结论

  • 重复SRT治疗局部或远处复发性脑转移瘤耐受良好,无3至4级毒性,且重复SRT未导致更多急性神经毒性。
  • 即使治疗超过10个脑转移瘤,等效全脑放疗剂量(VWBRT)仍较低。

研究设计与样本

  • 回顾性分析2010年至2020年间184例无既往或同期全脑放疗、因局部或远处脑转移复发接受2至6次SRT的患者的资料。
  • 共治疗915个脑转移瘤;SRT期间通过会诊记录剂量、皮质类固醇使用及神经系统症状,并按CTCAEv4评级。
  • 收集了79%脑转移瘤的剂量学特征,并创建了76.6%脑转移瘤的求和计划。

主要发现

  • 36%的患者在至少一次SRT期间出现急性毒性;无3级或4级毒性登记;1级或2级头痛是最常报告的症状。
  • 连续SRT sessions之间急性毒性发生率无显著差异。
  • 多因素分析中,急性毒性与放疗前使用皮质类固醇(OR=2.6;p=0.01)、BMV分级(高 vs. 低:OR=5.17;p=0.02)及SRT次数(3次 vs. 2次:OR=2.64;p=0.01)相关。
  • 等效全脑放疗剂量(VWBRT)中位数为47.9 ml;多因素分析中VWBRT与总GTV(p<0.001)及脑转移瘤数目(p<0.001)显著相关。
  • 即使治疗超过10个累积脑转移瘤,脑生物等效剂量(BED)中位数仍远低于全脑放疗所给剂量。

关键数值与推荐

  • 急性毒性按CTCAEv4评级。
  • 多因素分析显示放疗前使用皮质类固醇与急性毒性相关(OR=2.6;p=0.01)。
  • BMV分级高 vs. 低与急性毒性相关(OR=5.17;p=0.02)。
  • SRT次数3次 vs. 2次与急性毒性相关(OR=2.64;p=0.01)。
  • VWBRT中位数为47.9 ml。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Stereotactic radiation therapy (SRT) is a focal treatment for brain metastases (BMs); thus, 20 to 40% of patients will require salvage treatment after an initial SRT session, either because of local or distant failure. SRT is not exempt from acute toxicity, and the acute toxicities of repeated SRT are not well known. The objective of this study was to analyze the acute toxicities of repeated courses of SRT and to determine whether repeated SRT could lead to cumulative brain doses equivalent to those of whole-brain radiotherapy (WBRT). MATERIAL AND METHODS: Between 2010 and 2020, data from 184 patients treated for 915 BMs via two to six SRT sessions for local or distant BM recurrence without previous or intercurrent WBRT were retrospectively reviewed. Patients were seen via consultations during SRT, and the delivered dose, the use of corticosteroid therapy and neurological symptoms were recorded and rated according to the CTCAEv4. The dosimetric characteristics of 79% of BMs were collected, and summation plans of 76.6% of BMs were created. RESULTS: 36% of patients developed acute toxicity during at least one session. No grade three or four toxicity was registered, and grade one or two cephalalgy was the most frequently reported symptom. There was no significant difference in the occurrence of acute toxicity between consecutive SRT sessions. In the multivariate analysis, acute toxicity was associated with the use of corticosteroid therapy before irradiation (OR = 2.6; p = 0.01), BMV grade (high vs. low grade OR = 5.17; p = 0.02), and number of SRT sessions (3 SRT vs. 2 SRT: OR = 2.64; p = 0.01). The median volume equivalent to the WBRT dose (VWBRT) was 47.9 ml. In the multivariate analysis, the VWBRT was significantly associated with the total GTV (p < 0.001) and number of BMs (p < 0.001). Even for patients treated for more than ten cumulated BMs, the median BED to the brain was very low compared to the dose delivered during WBRT. CONCLUSION: Repeated SRT for local or distant recurrent BM is well tolerated, without grade three or four toxicity, and does not cause more acute neurological toxicity with repeated SRT sessions. Moreover, even for patients treated for more than ten BMs, the VWBRT is low.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Kuntz L, Le Fèvre C, Jarnet D, et al. Acute toxicities and cumulative dose to the brain of repeated sessions of stereotactic radiotherapy (SRT) for brain metastases: a retrospective study of 184 patients. Radiat Oncol. 2023. PMID: 36627646. doi:10.1186/s13014-022-02194-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。